This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Malic acid
- DrugBank Accession Number
- DB12751
- Background
Malic acid has been used in trials studying the treatment of Xerostomia, Depression, and Hypertension.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Malic acid (DB12751)
- Weight
- Average: 134.0874
Monoisotopic: 134.021523302 - Chemical Formula
- C4H6O5
- Synonyms
- Malic acid
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Acidosis Combination Product in combination with: Potassium hydroxide (DB11153) •••••••••••• ••••• •••••••••• •••••••• Used in combination to prevent Acidosis Combination Product in combination with: Calcium chloride (DB01164), Sodium chloride (DB09153), Magnesium chloride (DB09407), Potassium chloride (DB00761), Sodium acetate (DB09395) •••••••••••• •••••••• Used in combination to treat Acidosis Combination Product in combination with: Calcium chloride (DB01164), Potassium chloride (DB00761), Sodium chloride (DB09153), Sodium acetate (DB09395), Magnesium chloride (DB09407) •••••••••••• •••••••• Used in combination to treat Acute hypokalemia Combination Product in combination with: Potassium hydroxide (DB11153) •••••••••••• ••••• •••••••••• •••••••• Used in combination to treat Hot water burns (scalds) Combination Product in combination with: Salicylic acid (DB00936), Benzoic acid (DB03793) ••• ••• ••••••••••• •••••• ••••••••• •••••• ••••••••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Acerbine - Lösung Malic acid (21.5 mg/g) + Benzoic acid (1.5 mg/g) + Salicylic acid (0.4 mg/g) Solution Topical Pharmazeutische Fabrik Montavit Gmb H 1972-08-28 Not applicable Austria 
Acerbine - Salbe Malic acid (7 mg/g) + Benzoic acid (0.5 mg/g) + Salicylic acid (0.133 mg/g) Ointment Topical Pharmazeutische Fabrik Montavit Gmb H 1977-11-17 Not applicable Austria AKE 1100 GLUKOZLU IV SOLOSYONU, 1000 ML Malic acid (2.64 g/mL) + Acetylcysteine (0.25 g/mL) + Alanine (4.5 g/mL) + Arginine (3.6 g/mL) + D-glucose monohydrate (66 g/mL) + Glycerin (3.61 g/mL) + Glycine (4.2 g/mL) + Histidine (3.6 g/mL) + Isoleucine (1.5 g/mL) + Leucine (2.52 g/mL) + Lysine monohydrate (2.476 g/mL) + Methionine (1.6 g/mL) + Phenylalanine (1.062 g/mL) + Potassium chloride (1.865 g/mL) + Proline (4.5 g/mL) + Threonine (1.32 g/mL) + Tryptophan (0.6 g/mL) + Zinc chloride (3 mg/mL) Solution Intravenous FRESENİUS KABİ İLAÇ SAN. VE TİC. LTD. ŞTİ. 1995-03-08 2022-03-03 Turkey 
AKE 1100 GLUKOZLU IV SOLOSYONU, 500 ML Malic acid (2.64 g/mL) + Acetylcysteine (0.25 g/mL) + Alanine (4.5 g/mL) + Arginine (3.6 g/mL) + D-glucose monohydrate (66 g/mL) + Glycerin (3.61 g/mL) + Glycine (4.2 g/mL) + Histidine (3.6 g/mL) + Isoleucine (1.5 g/mL) + Leucine (2.52 g/mL) + Lysine monohydrate (2.476 g/mL) + Methionine (1.6 g/mL) + Phenylalanine (1.062 g/mL) + Potassium chloride (1.865 g/mL) + Proline (4.5 g/mL) + Threonine (1.32 g/mL) + Tryptophan (0.6 g/mL) + Zinc chloride (3 mg/mL) Solution Intravenous FRESENİUS KABİ İLAÇ SAN. VE TİC. LTD. ŞTİ. 1995-03-08 2022-03-03 Turkey AMINOPLASMAL-10% E INFUSION Malic acid (1.01 g/l) + Acetylcysteine (0.5 g/l) + Alanine (13.7 g/l) + Arginine (9.2 g/l) + Asparagine (3.27 g/l) + Aspartic acid (1.3 g/l) + Glutamic acid (4.6 g/l) + Glycine (7.9 g/l) + Histidine (5.2 g/l) + Isoleucine (5.1 g/l) + Leucine (8.9 g/l) + Lysine hydrochloride (5.6 g/l) + Magnesium acetate (0.56 g/l) + Methionine (3.8 g/l) + N-acetyltyrosine (1 g/l) + Ornithine hydrochloride (2.51 g/l) + Phenylalanine (5.1 g/l) + Potassium acetate (2.45 g/l) + Proline (8.9 g/l) + Serine (2.4 g/l) + Sodium acetate (3.95 g/l) + Sodium hydroxide (0.2 g/l) + Sodium phosphate, monobasic (1.4 g/l) + Threonine (4.1 g/l) + Tryptophan (1.8 g/l) + Tyrosine (0.3 g/l) + Valine (4.8 g/l) Injection Intravenous B. BRAUN SINGAPORE PTE LTD 1991-05-13 Not applicable Singapore 
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as beta hydroxy acids and derivatives. These are compounds containing a carboxylic acid substituted with a hydroxyl group on the C3 carbon atom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Hydroxy acids and derivatives
- Sub Class
- Beta hydroxy acids and derivatives
- Direct Parent
- Beta hydroxy acids and derivatives
- Alternative Parents
- Short-chain hydroxy acids and derivatives / Fatty acids and conjugates / Dicarboxylic acids and derivatives / Alpha hydroxy acids and derivatives / Secondary alcohols / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Alcohol / Aliphatic acyclic compound / Alpha-hydroxy acid / Beta-hydroxy acid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Dicarboxylic acid or derivatives / Fatty acid / Hydrocarbon derivative
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- C4-dicarboxylic acid, 2-hydroxydicarboxylic acid (CHEBI:6650)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 817L1N4CKP
- CAS number
- 6915-15-7
- InChI Key
- BJEPYKJPYRNKOW-UHFFFAOYSA-N
- InChI
- InChI=1S/C4H6O5/c5-2(4(8)9)1-3(6)7/h2,5H,1H2,(H,6,7)(H,8,9)
- IUPAC Name
- 2-hydroxybutanedioic acid
- SMILES
- OC(CC(O)=O)C(O)=O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000744
- KEGG Compound
- C00711
- PubChem Compound
- 525
- PubChem Substance
- 347828940
- ChemSpider
- 510
- BindingDB
- 92495
- 29209
- ChEBI
- 6650
- ChEMBL
- CHEMBL1455497
- Wikipedia
- Malic_acid
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2, 3 Completed Treatment Depression / Dry Mouth / Hypertension 1 Not Available Completed Treatment Hematological Malignancy 1 Not Available Recruiting Treatment Dry Mouth 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Topical Ointment Topical Injection Intravenous 0.5 g/l Injection Intravenous 0.25 g/1000ml Solution Parenteral Solution Intravenous Solution Intravenous 0.3675 g/1000ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 218.0 mg/mL ALOGPS logP -0.87 ALOGPS logP -1.1 Chemaxon logS 0.21 ALOGPS pKa (Strongest Acidic) 3.2 Chemaxon pKa (Strongest Basic) -3.9 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 94.83 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 24.88 m3·mol-1 Chemaxon Polarizability 10.91 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 122.0998017 predictedDarkChem Lite v0.1.0 [M-H]- 119.42592 predictedDeepCCS 1.0 (2019) [M+H]+ 122.8973017 predictedDarkChem Lite v0.1.0 [M+H]+ 122.26196 predictedDeepCCS 1.0 (2019) [M+Na]+ 122.1527017 predictedDarkChem Lite v0.1.0 [M+Na]+ 130.68065 predictedDeepCCS 1.0 (2019)
Drug created at October 21, 2016 00:01 / Updated at February 21, 2021 18:53